Fiducient Advisors LLC Decreases Stake in Bristol-Myers Squibb (NYSE:BMY)

Fiducient Advisors LLC lowered its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 30.2% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,927 shares of the biopharmaceutical company’s stock after selling 2,992 shares during the quarter. Fiducient Advisors LLC’s holdings in Bristol-Myers Squibb were worth $358,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BMY. Diversify Wealth Management LLC lifted its holdings in Bristol-Myers Squibb by 9.6% during the third quarter. Diversify Wealth Management LLC now owns 12,837 shares of the biopharmaceutical company’s stock worth $681,000 after acquiring an additional 1,122 shares during the period. Pinnacle Associates Ltd. increased its position in shares of Bristol-Myers Squibb by 36.3% during the 3rd quarter. Pinnacle Associates Ltd. now owns 266,041 shares of the biopharmaceutical company’s stock valued at $13,651,000 after purchasing an additional 70,905 shares during the last quarter. First Trust Direct Indexing L.P. raised its stake in shares of Bristol-Myers Squibb by 54.8% during the 3rd quarter. First Trust Direct Indexing L.P. now owns 33,428 shares of the biopharmaceutical company’s stock worth $1,730,000 after purchasing an additional 11,831 shares during the period. Gimbal Financial bought a new position in Bristol-Myers Squibb during the third quarter valued at about $208,000. Finally, Pathway Financial Advisers LLC grew its position in shares of Bristol-Myers Squibb by 38,392.1% during the 3rd quarter. Pathway Financial Advisers LLC now owns 431,112 shares of the biopharmaceutical company’s stock valued at $22,306,000 after acquiring an additional 429,992 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

BMY has been the topic of several research analyst reports. BMO Capital Markets reiterated a “market perform” rating and issued a $48.00 price objective on shares of Bristol-Myers Squibb in a research note on Monday, September 23rd. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. TD Cowen raised their price objective on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research report on Monday, October 7th. UBS Group lifted their price objective on Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a research note on Wednesday, October 9th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $50.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, October 18th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Bristol-Myers Squibb presently has an average rating of “Hold” and an average target price of $52.38.

Bristol-Myers Squibb Stock Up 0.3 %

Shares of Bristol-Myers Squibb stock opened at $52.68 on Thursday. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.02 and a current ratio of 1.16. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $55.03. The company’s 50 day moving average price is $50.98 and its 200-day moving average price is $46.48. The stock has a market capitalization of $106.79 billion, a price-to-earnings ratio of -16.99, a P/E/G ratio of 13.75 and a beta of 0.46.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 4.56%. The ex-dividend date is Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.